Paclitaxel/carboplatin with or without sorafenib in the first‐line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute

By  

Cancer Medicine, Vol. 4, Iss. 5, 2015-05 ,pp. : 673-681

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized Study Comparing Carboplatin/Cyclophosphamide and Cisplatin/Cyclophosphamide as First-Line Treatment in Patients with Stage III/IV Epithelial Ovarian Cancer and Small Volume Disease

By Meerpohl H.G.   Sauerbrei W.   Kuhnle H.   Schumacher M.   Pfleiderer A.   German Ovarian Cancer Study Group GOCA  

Gynecologic Oncology, Vol. 66, Iss. 1, 1997-07 ,pp. : 75-84

Elsevier

Access to resources Recommend Favorite

First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients

By Romanini A.   Tanganelli L.   Carnino F.   Fanucchi A.   Lionetto R.   Pastorino S.   Cosio S.   Gadducci A.   Conte P.F.  

Gynecologic Oncology, Vol. 89, Iss. 3, 2003-06 ,pp. : 354-359

Elsevier

Access to resources Recommend Favorite

Results of Reinduction Therapy with Paclitaxel and Carboplatin in Recurrent Epithelial Ovarian Cancer

By Gronlund B.   Hogdall C.   Hansen H.H.   Engelholm S.A.  

Gynecologic Oncology, Vol. 83, Iss. 1, 2001-10 ,pp. : 128-134

Elsevier

Access to resources Recommend Favorite

Is Age a Barrier to the Aggressive Treatment of Ovarian Cancer with Paclitaxel and Carboplatin?

By Higgins R.V.   Naumann R.W.   Gardner J.   Hall J.B.  

Gynecologic Oncology, Vol. 75, Iss. 3, 1999-12 ,pp. : 464-467

Elsevier

Access to resources Recommend Favorite